Kornimate/medical-research-clean huggingface dataset:
brain enhancement training towards elders resilience to aging

Conditions: Age-related Cognitive Decline

Summary: this study is a parallel arm, double-blind, randomized, controlled clinical trial to assess the efficacy of an experimental software program designed to improve cognitive functions versus a computer-based software control. both the study and the software being investigated meet the criteria of non-significant risk.

the primary objective of this study is to evaluate the effects of the experimental treatment (cognitive training) further outlined in this protocol on the cognitive abilities (e.g., processing speed, attention, working memory, and executive function), brain functionality, functional status and quality of life of individuals with age-related cognitive decline as compared to a computer-based active control.

Eligibility criteria:
inclusion criteria: * participant must be 65 years of age or older * participant must be a fluent english speaker * participant must have adequate sensorimotor capacity to perform the program, including visual capacity adequate to read from a computer screen at a normal viewing distance, auditory capacity adequate to understand normal speech, and motor capacity adequate to control a computer mouse * participant must not have evidence of dementia as indicated by the montreal cognitive assessment (moca) exclusion criteria: * participant with any medical illnesses, injuries or conditions predisposing to imminent functional and/or cognitive decline * participant requiring caregiver assistance in dressing/personal hygiene * participant with severe visual deficits (including visual neglect, partial field cuts, anopias) and/or severe hearing deficit that would prevent use of the computerized treatment program * participant with recent participation of computer-delivered cognitive training within 2 years of consent * participant with claustrophobia or any other contraindication to mri scanning * participant with inability to complete a 1-hour mri * pregnant women * participant with any implanted devices above the waist (e.g., cardiac pacemaker or auto-defibrillators, neural pacemaker, aneurysm clips, cochlear implant, metallic bodies in the eye or central nervous system, any form of wires or metal devices that may concentrate radio frequency fields) * participants with active suicidal ideation with specific plan and intent or suicide-related behaviors within 2 months of consent as measured by the columbia-suicide severity rating scale (c-ssrs)
inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy

Summary: objective the objective of the study is to assess the structural and functional cardiac effects of treatment with losartan in patients with hypertrophic cardiomyopathy (hcm). design the study is a randomized, placebo-controlled, double-blinded trial. the follow-up period is 12 months. 130 patients with hcm will be included in predefined subgroups. genotype positive relatives with borderline hypertrophy (\> 13 mm) will also be included. data on individuals with borderline hypertrophy will be analysed separately from the rest of the cohort. primary outcome ventricular hypertrophy assessed as left ventricular mass and maximal wall thickness.


Eligibility criteria:
inclusion criteria: * hypertrophic cardiomyopathy * \> 18 years * sinus rhythm exclusion criteria: * ef \< 50 % * treatment with ras-inhibitor * contraindications to losartan

Keywords: hypertrophic cardiomyopathy hypertrophic obstructive cardiomyopathy hypertrophy losartan angiotensin ii receptor antagonist
protective effect of phenytoin on glaucoma

Conditions: Primary Open Angle Glaucoma; Secondary Open Angle Glaucoma; Narrow-Angle Glaucomas; Normal Tension Glaucoma

Summary: since glaucoma is considered an optic neuropathy, new treatments for glaucoma are being continuously investigated, including neuroprotection. previous studies implied that phenytoin, a potent anti-convulsive drug, has a neuroprotective role, and na+ channels blockage was suggested as a possible mechanism. this study predicts that glaucoma patients taking phenytoin will have a less advanced glaucoma as compared to patients not taking the drug. glaucoma severity will be determined by visual acuity, visual fields, optic disc cupping and nerve fiber layer thickness

the study will examine adult patients who suffer from glaucoma and epileptic disorders on the same time. the study group will include glaucoma patients, being treated with oral phenytoin for their epileptic disorder. the study group will be compared to 2 control groups: * glaucoma patients with epileptic disorder,receiving different medication than phenytoin * glaucoma patients with no epileptic disorder. 4 parameters will be evaluated for all groups: 1. best corrected visual acuity 2. optic disc cupping 3. visual fields and general perimetric indices 4. peripapillary retinal nerve fiber layer. every participant in the study,after giving his informed consent, will be evaluated by a senior ophthalmologist in a single office appointment. the appointment will include a visual acuity, complete ophthalmic examination,humphrey perimetric visual field testing and peripapillary rnfl thickness measurement by oct. no drug or other treatment will be given to the participants after data collection, average +/-standard deviation for the 4 parameters will be compared between the 3 groups. student t-test and one- way anova will be used for statistical analysis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of glaucoma * chronic treatment with phenytoin for any indication exclusion criteria: * pregnancy * visual acuity less then 6/60

Keywords: glaucoma phenytoin retinal nerve fiber layer corrected pattern standard deviation visual acuity optic disc cupping
positron emission tomagraphy (pet) study following a single oral dose of opc-34712

Conditions: Schizophrenia

Summary: determine the degree of striatal d2 receptor occupancy induced by opc-34712 at differenht dose levels in healthy volunteers.

subjects will receive a dose of study medication and will undergo a pet scan at 4 hrs and 23.5 hours post dose. subjects will remain in the clinic from day-1 to day 7 for pk sample collection and safety monitoring. subjects will return to the clinic on day 10 for a follow-up safety assessment.

Eligibility criteria:
inclusion criteria: * males and non-child bearing potential females between 18 and 45 years of age, inclusive. * bmi between 19 and 32 kg/m2, inclusive. exclusion criteria: * condition or history which may present a safety concern to the subject or interfere with outcome variables. * history of or current drug or alcohol abuse, hepatitis, aids, or drug allergy. * use of prescription, over-the-counter, or herbal medication, or vitamin supplements within 14 days or antibiotics within 30 days. * use of tobacco products or daily exposue to second hand smoke. * blood pressure higher than 140/90 mmhg or lower than 100/50 mmhg: heart rate outside 40 to 90 beats/minute. * history of serious mental disorder.

Keywords: healthy volunteers phase i pet scan
cryotherapy versus dexamethasone on postoperative pain in permanent mandibular molars

Conditions: Pulpitis - Irreversible

Summary: the goal of this clinical trial was to evaluate cryotherapy versus dexamethasone on the intensity of postoperative pain in root canal treatment procedures in mandibular first molar teeth with symptomatic irreversible pulpitis. the main question it aims to answer is: * does controlled irrigation with cold saline in root canal treatment reduce the severity of postoperative pain? * does controlled irrigation with dexamethasone in root canal treatment reduce the severity of postoperative pain? in the cryotherapy group, unlike the control and dexamethasone group, the root canals were irrigated with 2 °c salin solution in final irrigation. in the dexamethasone group, unlike the control and cryotherapy group, the root canals were irrigated with 1 ml dexamethasone solution in final irrigation.


Eligibility criteria:
inclusion criteria: * vital mandibular first and second molars with 3 root canals that responded positively to the cold test and electric pulp test * patients who had not taken analgesics or antibiotics in the last 24 hours before the procedure were included in the study. exclusion criteria: * devital mandibular first and second molars that responded negatively to cold tests and electric pulp tests * mandibular first and second molars with poor periodontal status (pocket depth \> 4 mm), * mandibular first and second molars with 4 or more root canals detected radiographically or after opening the endodontic access cavity were excluded from the study.

Keywords: cryotherapy irrevesible pulpitis dexamethasone postoperative pain
effentora® in clinical practice - a non-interventional study to evaluate satisfaction and tolerability

Conditions: Cancer; Pain

Summary: aim of this non-interventional study is to investigate the tolerability of effentora® in cancer pain patients with breakthrough pain under real-life conditions in clinical practice.

in addition to the effectiveness of effentora® therapy, safety, general feasibility and the impact of therapy on the patients' quality of life are of interest.

Eligibility criteria:
inclusion criteria: * decision to start treatment with effentora * prescription in accordance with summary of product characteristics (smpc) * personally signed and dated informed consent document exclusion criteria: * any subject considered unsuitable according to smpc

Keywords: breakthrough cancer pain
icotinib in advanced metastatic patients with nsclc previously treated with chemotherapy

Conditions: Non-small Cell Lung Cancer

Summary: this study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic nsclc after failure of at least one platinum-based chemotherapy regimen.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed locally advanced/metastatic (stage iiib/stage iv, using the american joint committee on cancer \[ajcc\] 6th edition of tumor-node-metastasis \[tnm\] staging system) nsclc patients * progressed after at least one platinum-based chemotherapy regimen at entry * eastern cooperative oncology group (ecog) performance status (ps) 0-2 * at least one measurable lesion by response evaluation criteria in solid tumors version 1.0 * adequate hematologic and biochemical values exclusion criteria: * patients with symptomatic brain metastases * malignant tumor within the previous five years * severe infection; congestive heart failure * previous treatment with drugs targeting egfr * history of interstitial lung disease
incidence of postoperative sore-throat incidence

Conditions: Sore-throat

Summary: postoperative sore throat is a distressing but frequent symptom presented by the patients on the floor upon awakening from general anesthesia, where endotracheal intubation is part of the anesthetic protocol. its incidence ranges between 21-71.8%. good skills and availability of trained staff to cause minimal tissue damage are expected to reduce the incidence. risks factors associated will be analyzed.

post-operative sore throat (post) is a common complication of endotracheal intubation. it ranges from 21 to 71.8 %. various factors contribute to the development of post, like, female sex, smoking, intubation difficulty and suxamethonium use, high endotracheal cuff pressure, airway suctioning, long duration of surgery, mucosal injury with laryngoscopy, or pharyngeal airway use and larger size endotracheal tubes \[9\]. post has also been associated with laryngeal masks, injury with laryngoscopy, or pharyngeal airway use and larger size endotracheal tubes. basically it is mucosal damage of the throat and trachea which releases inflammatory mediators and produces soreness. post leads to postoperative dissatisfaction. patients of post are uncontended following general anesthesia. its preemptive amelioration, has been studied using various pharmacological interventions. the list includes, but is not limited to, benzydamine hydrochloride (bh), aspirin, ketamine, lidocaine and dexamethasone. there is limited evidence based literature available about the incidence of post in the investigator's locality in the country. the investigators plan to collect data in general ot of rehman medical institute (rmi), peshawar. the city of peshawar is the largest city of khyber pakhtunkhwa, a province of pakistan, having a population of approximately 2 million. the objectives of our study is to know the magnitude of the problem and ascertain factors associated with postoperative sore throat among patients undergoing elective surgery under general anesthesia with endotracheal intubation.

Eligibility criteria:
inclusion criteria: * any patient of either gender aged 18- 60 years * patients of american society of anesthesiologists (asa) physical status 1 and 2 receiving general anesthesia with ett exclusion criteria: * patients having asa 3 or above physical status * recent or ongoing upper respiratory tract infection (urti) * patients going to icu intubated
two formulations and concentrations of epinastine nasal spray versus azelastine nasal solution for allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the objectives of this study were to: * examine the tolerability of two formulations and two dose concentrations of epinastine. * select formulation(s) of epinastine for future studies by evaluating the individual sensory attribute scores of the nasal spray evaluation questionnaire (nseq) collected after each study drug administration and the subject preference ranking assessed at the completion of the study. * compare the preference of two formulations and two dose concentrations of epinastine compared to azelastine following a single dose of each in a randomized, double-blind, two-cohort, three-period crossover design.


Eligibility criteria:
inclusion criteria: * between ages 18-70 * history of sar or par for 1 year * mild symptoms exclusion criteria: * asthma or rad * respiratory tract infection within 14 days prior to screening
prevalence of the eosinophilic phenotype among severe asthma patients

Conditions: Severe Asthma

Summary: the purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the astrazeneca international region. the prevalence of an atopic phenotype and asthma control, will also be studied.

to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the astrazeneca international region. the prevalence of an atopic phenotype and the status of asthma control, will also be studied. it is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.

Eligibility criteria:
inclusion criteria patients must fulfil all of the following inclusion criteria to be included in the study: * male or female patient, aged 12 years or older by the time of study entry * patient visiting a participating center for a routine clinical appointment * patient is willing and able to provide a blood sample for ige and eosinophil levels determination as part of their routine clinical visit * diagnosis of severe asthma for at least one year as defined by: * treatment with guidelines-suggested medications for global initiative for asthma (3) steps 4-5 asthma * patients or their legal guardian, who voluntarily sign and date the informed consent form prior to study entry. exclusion criteria * patients with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory condition beyond severe asthma * an acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study patients who are currently under a biologic therapy to treat their severe asthma

Keywords: eosinophilic asthma severe asthma prevalence phenotype atopic phenotype eosinophilic phenotype
efficacy and safety of three different latanoprost 0,005% eyedrops in subjects affected by primary open angle glaucoma

Conditions: Intraocular Pressure (IOP); Tear Break-Up Time

Summary: this study examines efficacy and tolerability of 3 different latanoprost 0.005% eyedrops preparations, commercially available in italy, in subjects affected by primary open angle glaucoma.

prospective, randomized, single blinded study of the duration of 3 months, involving subjects affected by poag or oh under therapy with different latanoprost drugs (galaxia, iopize or latanoprost rathiopharm). a total of 120 patients affected by poag or oh newly diagnosed or already under topical therapy. will be recruited. after a recruitment visit to assest eligibility of each subject, a "run-in" therapy composed of timolol 0,5% 2 drops per day will be prescribed for 4 weeks. then a baseline visit will be performed to evaluate iop values and adverse effects in each subject. all subjects elegible for a therapy with a single dose of latanoprost will be randomized into 3 arms. after 4 weeks of therapy a second visit will be made to assest iop changes and safety. therapy will be continued for another 4 weeks, and after that, a final visit will be made.

Eligibility criteria:
inclusion criteria: * age ranged between 18 and 80 * untreated iop ranged between 21 and 30 mmhg * iop already treated with a single drug (monotherapy) ranged between 10 and 28 mmhg exclusion criteria: * history of adverse events or any controindication to drugs administred during sperimentation, i. e. latanoprost and timolol. * narrow or closed iridocorneal angle. * history of acute angle-closure glaucoma. * previous laser trabeculoplasty within 3 months before screening. * severe visual field defects within 10° from fixation in at least one eye (at least 2 points with a p\<0,5 in a pattern deviation map obtained from a reliable 24-2 sita standard sap). * history of refractive surgery or any keratoplasty procedure, corneal opacities or diseases that make not suitable applanation tonometry. * use of contact lenses. * bcva less than 20/200. * ocular inflammation/infection occurring within three months before screening. * history of bradicardia, systemic hypotension, bundle branch or any atrio-ventricular block * asthma * women of childbearing potential who were not using adequate contraceptive methods or who were pregnant or nursing

Keywords: latanoprost iop
vessel wall enhancement in giant cell arteritis

Conditions: Giant Cell Arteritis

Summary: the research study is being conducted to determine the utility of magnetic resonance imaging (mri) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. the target population includes patient diagnosed with giant cell arteritis (gca; temporal arteritis).

after signing the consent form, participants will complete an mri scan within 2 weeks of enrollment and fill out questionnaires related to their disease. follow up visits and mri scans may occur at 1-month, 6-months, 12-months after the initial mri scan or at the time of relapse.

Eligibility criteria:
inclusion criteria: * participant must be in one of the following groups: 1. suspected new diagnosis of gca 2. suspected relapse of gca (new or worsening symptoms attributed to active gca) in patient with previously established diagnosis of gca * the participant must have (or previously had) cranial manifestations related to or concerning for gca including: visual symptoms, headache, temporal artery tenderness, jaw claudication, scalp tenderness, or stroke * participant must be within 14 days of initiating or escalating systemic glucocorticoids (e.g., prednisone) or have ongoing cranial symptoms concerning for active disease at time of baseline mri. * participants who are receiving a clinically-indicated mri at the time of enrollment may participate even if they meet exclusion criteria of creatinine clearance less than 30 ml/min or mild gadolinium allergy * participants must sign the informed consent form exclusion criteria: * contra-indication to receiving mri including: * implanted medical devices, pacemaker and metallic foreign fragments inside body or orbit * known gadolinium allergy * estimated glomerular filtration rate less than 30 ml/min/1.73m2 * claustrophobia * women who are pregnant or nursing

Keywords: temporal arteritis juvenile temporal arteritis horton's giant cell arteritis horton's disease horton giant cell arteritis horton disease giant cell aortitis giant cell aortic arteritis cranial arteritis
a clinical evaluation of metal ion release from metal-on-metal cementless total hip arthroplasty

Conditions: Osteoarthritis; Avascular Necrosis; Traumatic Arthritis; Rheumatoid Arthritis

Summary: a clinical evaluation to determine metal ion release from 4th generation metal-on-metal hip articulating surfaces in cementless total hip arthroplasty.

this evaluation is being conducted to investigate the extent of metal ion release and its incorporation into the surrounding tissue resulting from metal on metal articulating surfaces in cementless total hip arthroplasty. the amount of metallic ions released post operatively will be assessed by the concentration of cobalt, chromium and molybdenum present in urine and analysed by i.c.p.m.s. (inductive coupled plasma mass spectroscopy). the amounts of metallic ions released will be related to the hip function and range of motion measured pre-operatively and post-operatively. secondary performance of the metal-on-metal articulation will be determined by radiographic evaluation and incidence of complications / revision rates.

Eligibility criteria:
inclusion criteria: * subjects selected for this evaluation will be grouped by initial diagnosis into one of the following diagnostic groups: * non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and traumatic arthritis. * rheumatoid arthritis. * selection of subjects for this evaluation should include the following considerations: * patients under 70 years of age. * willing to return for follow-up evaluations. * no bias to sex. exclusion criteria: